---
title: "Coherus Q2 FY26 net loss narrows 25.67% to $33.3 million; revenue rises 39.51% to $14.3 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295022912.md"
description: "Coherus Oncology reported Q2 FY26 revenue of $14.3 million, a 39.51% increase year-over-year, driven by strong demand for LOQTORZI. Net loss narrowed 25.67% to $33.3 million due to reduced R&D expenses and lower trial costs. Cash reserves decreased to $105.3 million from December 2025 levels."
datetime: "2026-08-05T22:10:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295022912.md)
  - [en](https://longbridge.com/en/news/295022912.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295022912.md)
---

# Coherus Q2 FY26 net loss narrows 25.67% to $33.3 million; revenue rises 39.51% to $14.3 million

-   Coherus Oncology posted Q2 2026 revenue of USD 14.3 million, up 39.53% from a year earlier. \* Net loss from continuing operations narrowed to USD 33.3 million, or USD 0.22 per share, from USD 44.9 million, or USD 0.39 per share. \* LOQTORZI net revenue rose 15% from Q1 2026 to USD 13.6 million, with strong demand and the most new patient starts since launch. \* R&D expense fell to USD 21.4 million from USD 26.3 million, on reduced headcount and lower trial and manufacturing costs. \* Cash, cash equivalents and marketable securities totaled USD 105.3 million at June 30, 2026, down from USD 172.1 million at Dec. 31, 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CHRS.US](https://longbridge.com/en/quote/CHRS.US.md)

## Related News & Research

- [Q3 EPS Estimates for Coherus Oncology Cut by HC Wainwright](https://longbridge.com/en/news/296058187.md)
- [Coherus Oncology declares CVR dividend tied to sale of remaining biosimilar assets](https://longbridge.com/en/news/296148200.md)
- [Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights | CHRS Stock News](https://longbridge.com/en/news/296148922.md)
- [Baker Hughes declares Q3 2026 dividend of R$ 0.81 per unit](https://longbridge.com/en/news/296392545.md)
- [Masoval to present Q2 2026 results in investor briefing](https://longbridge.com/en/news/296509895.md)